Helus Pharma Reports Fiscal Q2 Results, Positive Phase 3 Study Data
Helus Pharma reported fiscal second-quarter 2027 results and positive topline results from its Phase 3 APPROACH study of HLP003 as an adjunctive treatment for major depressive disorder.
Helus Pharma (HELP) shares drew significant investor attention in Monday’s premarket trade after the company reported its fiscal second-quarter 2027 results and announced positive topline results from its Phase 3 APPROACH study evaluating HLP003 as an adjunctive treatment for major depressive disor…